Berenberg Bank Reaffirms “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Berenberg Bank in a research report issued on Wednesday, MarketBeat.com reports. They presently have a GBX 140 ($1.81) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price target would indicate a potential downside of 98.75% from the stock’s previous close.

Several other research analysts have also weighed in on the stock. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Friday, March 7th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($97.65).

AstraZeneca Trading Down 0.3 %

LON AZN opened at £111.96 ($144.95) on Wednesday. The company’s fifty day simple moving average is £115.78 and its 200-day simple moving average is £112.80. The stock has a market cap of £215.41 billion, a P/E ratio of 30.69, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a 52 week low of GBX 9,670 ($125.19) and a 52 week high of £133.88 ($173.33). The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.